Rubius Therapeutics, Inc. (RUBY) has 33 open-market insider trades by 14 insiders since 2018. The most active filer is Christopher L. Carpenter.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Christopher L. Carpenter | — | — | 6 | $3.0M | 2019-12-16 |
| Noubar Afeyan | Dir10% Owner | — | 1 | $2.0M | 2021-03-19 |
| David R. Epstein | Dir | — | 5 | $1.9M | 2022-04-21 |
| Jonathan Symonds | Dir | — | 1 | $575K | 2018-07-20 |
| Maiken Keson-Brookes | CLOSecretary | — | 2 | $524K | 2022-02-01 |
| Robert Langer | Dir | — | 4 | $417K | 2019-10-14 |
| Torben Straight Nissen | Pres | — | 1 | $242K | 2019-07-24 |
| Francis M. Cuss | Dir | — | 1 | $230K | 2018-07-20 |
| Christina M. Coughlin | — | — | 1 | $210K | 2020-04-22 |
| Pablo J. Cagnoni | CEOPres | — | 4 | $147K | 2023-02-01 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Dannielle Appelhans | President | Sell | $1K | 2023-02-24 |
| Pablo J. Cagnoni | Director | Sell | $2K | 2023-02-01 |
| Dannielle Appelhans | President | Sell | $970 | 2023-02-01 |
| Laurence A. Turka | Chief Scientific Officer | Sell | $622 | 2023-01-31 |
| Pablo J. Cagnoni | Director | Sell | $2K | 2023-01-31 |
| Dannielle Appelhans | COO | Sell | $5K |
Companies that share insiders with RUBY, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2022-08-10 |
| David R. Epstein | Director | Buy | $43K | 2022-04-21 |
| Pablo J. Cagnoni | President | Sell | $44K | 2022-02-01 |
| Maiken Keson-Brookes | Secretary | Sell | $18K | 2022-02-01 |
| Laurence A. Turka | Chief Scientific Officer | Sell | $17K | 2022-02-01 |
| Noubar Afeyan | Director & 10% Owner | Buy | $2.0M | 2021-03-19 |
| Maiken Keson-Brookes | CLO & Secretary | Sell | $1.0M | 2021-03-15 |
| David R. Epstein | Director | Sell | $797K | 2021-02-11 |
| David R. Epstein | Director | Sell | $2.9M | 2021-02-08 |
| Christina M. Coughlin | — | Buy | $210K | 2020-04-22 |